Science Friday

Study Finds COVID mRNA Vaccines Boost Cancer Treatment

November 10, 2025

Key Takeaways Copied to clipboard!

  • New research presented on *Science Friday* suggests that receiving a COVID mRNA vaccine around the time of immune therapy significantly increased survival rates (doubling the chance of being alive at three years) for patients with lung cancer and melanoma. 
  • The mechanism behind this benefit appears to be the mRNA vaccine acting as a 'siren' to wake up immune cells within the tumor, unleashing a Type 1 interferon response that sensitizes tumors to existing immunotherapies, and this effect is not unique to the COVID-19 vaccine. 
  • Despite this major potential breakthrough in cancer therapy, the federal government is currently slashing funding for mRNA research, which experts warn could significantly delay the development of optimized, off-the-shelf mRNA cancer vaccines. 

Segments

Introduction and Study Overview
Copied to clipboard!
(00:00:00)
  • Key Takeaway: COVID mRNA vaccines show an unanticipated benefit by making cancer treatments more effective.
  • Summary: The Science Friday episode introduces new research indicating that patients receiving a COVID mRNA vaccine lived longer when undergoing cancer treatment compared to unvaccinated counterparts. This finding is particularly notable as it emerges while federal funding for mRNA research is being cut. Host Ira Flatow introduces the lead study author, Dr. Adam Grippin, and vaccine expert Dr. Eric Topol.
Study Findings and Survival Data
Copied to clipboard!
(00:02:46)
  • Key Takeaway: Vaccinated lung cancer and melanoma patients had double the chance of survival at three years when receiving immune therapy.
  • Summary: Dr. Grippin explains that analyzing over a thousand patients treated with immune therapies showed those vaccinated near the time of treatment lived significantly longer. Specifically, for lung cancer and melanoma patients treated with immune-directed therapies, the chance of being alive three years post-treatment was about double for the vaccinated group. The team validated these findings in animal models and is planning a randomized phase three clinical trial.
Mechanism of Action Explained
Copied to clipboard!
(00:04:05)
  • Key Takeaway: The mRNA vaccine acts like a siren, waking up immune cells inside the tumor and training them to kill cancer.
  • Summary: Dr. Topol elaborates that the mechanism is independent of the SARS-CoV-2 virus, suggesting any mRNA vaccine could work by unleashing the Type 1 interferon response. This process changes tumors from ‘cold’ to ‘hot,’ which primes them for success when immunotherapy drugs like checkpoint inhibitors are administered. This finding represents a significant jump for solid tumor cancer therapy.
Future of mRNA Vaccine Development
Copied to clipboard!
(00:06:40)
  • Key Takeaway: Future, specifically designed mRNA vaccines are expected to be far more effective than the current COVID-19 vaccine for cancer treatment.
  • Summary: Dr. Grippin confirms that any messenger RNA generates a similar effect in animal models, but researchers are now designing better, non-COVID-specific mRNA vaccines intended for this purpose. Dr. Topol notes that the current COVID vaccine response (a 280-fold increase in Type 1 interferon) can be scaled up into the thousands-fold with optimized mRNA platforms, such as self-amplifying mRNA being developed elsewhere.
Implications and Next Steps
Copied to clipboard!
(00:07:53)
  • Key Takeaway: The discovery offers a potential off-the-shelf therapy that could be implemented quickly alongside personalized vaccines.
  • Summary: Experts stress that while the results are exciting, randomized clinical trials are necessary before changing standard patient care, though Dr. Topol suggests the data is compelling enough to consider immediate application. This approach offers an ‘off-the-shelf’ solution that avoids the laborious personalization required for some other emerging cancer vaccines. The hope is to use this vaccine to awaken the immune system, followed by personalized reinforcements.